Skye Bioscience, Inc. Loss Contingency, Estimate of Possible Loss
Skye Bioscience, Inc. (SKYE) had Loss Contingency, Estimate of Possible Loss of $5.42 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Commitment and Contingencies › Loss Contingency
us-gaap:LossContingencyEstimateOfPossibleLoss · last filed 2026-08-14
- 2026-06-30: Loss Contingency, Estimate of Possible Loss $5.42M.
- 2026-03-31: Loss Contingency, Estimate of Possible Loss $2.57M.
- 2025-09-30: Loss Contingency, Estimate of Possible Loss $2.05M.
- 2025-06-30: Loss Contingency, Estimate of Possible Loss $1.81M.
| Period end | Loss Contingency, Estimate of Possible Loss |
|---|---|
| 2026-06-30 | $5.42M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $2.57M 10-Q · filed 2026-05-11 |
| 2025-09-30 | $2.05M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $1.81M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.91M 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |